StoxDr. Reddy's Laboratories vs Lupin: share price & financials comparison
NSE: DRREDDY vs LUPIN · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Dr. Reddy's Laboratories vs Lupin at a glance
Dr. Reddy's Laboratories (DRREDDY) has a market capitalisation of ₹1,15,230 Cr, against ₹90,559 Cr for Lupin (LUPIN). Over the past year Dr. Reddy's Laboratories has returned +15.0%, compared with -0.8% for Lupin. On valuation, Lupin trades at a lower P/E of 17.4 versus 41.2. Lupin earns a higher return on equity (21.6% vs 7.2%). Dr. Reddy's Laboratories comes out ahead on financial health, momentum and technicals. Lupin comes out ahead on size, valuation, profitability and growth. Across the scored metrics below, Dr. Reddy's Laboratories leads on 7 and Lupin on 11. On StoxGud's 10-point checklist, Dr. Reddy's Laboratories scores 5/10 and Lupin scores 6/10.
| Metric | Dr. Reddy's Laboratories | Lupin |
|---|---|---|
| Size | ||
| Market cap | ₹1,15,230 Cr | ₹90,559 Cr |
| Revenue (latest FY) | ₹33,700 Cr | ₹27,958 Cr |
| Net profit (latest FY) | ₹4,196 Cr | ₹5,333 Cr |
| Valuation | ||
| P/E | 41.2 | 17.4 |
| P/B | 2.97 | 3.77 |
| Dividend yield | 0.58% | 0.61% |
| Profitability | ||
| Return on equity | 7.2% | 21.6% |
| Net profit margin | 8.5% | 16.9% |
| Operating margin | 14.7% | 30.1% |
| Growth | ||
| Revenue growth (YoY) | -1.5% | +11.1% |
| Net profit growth (YoY) | -31.3% | -21.8% |
| Revenue CAGR (multi-year) | +12.1% | +13.0% |
| Financial health | ||
| Debt to equity | 0.15 | 0.23 |
| Momentum | ||
| 1-month return | +11.3% | +1.4% |
| 1-year return | +15.0% | -0.8% |
| 3-year CAGR | +8.4% | +19.1% |
| 5-year CAGR | +7.2% | +16.0% |
| 10-year CAGR | +7.6% | +3.2% |
| Distance from 52W high | -0.5% | -21.3% |
| Technicals | ||
| RSI (14) | 85 | 61 |
| Price vs 200-day avg | +10.1% | -11.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Dr. Reddy's Laboratories | Lupin |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✗ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 5/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Dr. Reddy's Laboratories or Lupin?
Dr. Reddy's Laboratories has a market cap of ₹1,15,230 Cr and Lupin has a market cap of ₹90,559 Cr as of 13 Nov 2026.
Which has a lower P/E, Dr. Reddy's Laboratories or Lupin?
Lupin has the lower P/E: Dr. Reddy's Laboratories trades at 41.2 and Lupin at 17.4.
Which gave better returns in the last year, Dr. Reddy's Laboratories or Lupin?
Dr. Reddy's Laboratories did better: Dr. Reddy's Laboratories returned +15.0% and Lupin returned -0.8% over one year.
What is the difference between Dr. Reddy's Laboratories and Lupin?
Both are NSE-listed companies in Healthcare. Dr. Reddy's Laboratories is about 1.3 times the size of Lupin by market cap. In the latest financial year Dr. Reddy's Laboratories reported revenue of ₹33,700 Cr and Lupin ₹27,958 Cr. Operating margin is 14.7% for Dr. Reddy's Laboratories and 30.1% for Lupin. Debt to equity is 0.15 for Dr. Reddy's Laboratories and 0.23 for Lupin.
Which is better, Dr. Reddy's Laboratories or Lupin?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Dr. Reddy's Laboratories leads on 7 and Lupin on 11. Dr. Reddy's Laboratories is ahead on financial health, momentum and technicals. Lupin is ahead on size, valuation, profitability and growth. On StoxGud's rules-based checklist Dr. Reddy's Laboratories scores 5/10 and Lupin scores 6/10. This is information, not advice: consult a SEBI-registered adviser before investing.